Please login to the form below

Not currently logged in
Email:
Password:

non-alcoholic steatohepatitis drugs

This page shows the latest non-alcoholic steatohepatitis drugs news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Roche enters NASH race with deal to buy Jecure

Company joins Novartis, Pfizer and others in nascent market. Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, ... Roche is playing catch-up with a host of other companies

Latest news

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics. Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) ... pipeline. The acquisition puts Allergan in a race to

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....